Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA DEMONSTRATED BENEFICIAL BACTERIAL TAXA PERSIST IN FECAL SAMPLES FROM PATIENTS WITH RCDI DESPITE MULTIPLE PRIOR CDI TREATMENTS WITH THE ANTIBIOTIC STANDARDS OF CARE, VANCOMYCIN (VAN) AND/OR FIDAXOMICIN (FDX) FOLLOWING ACUTE TREATMENT WITH IBEZAPOLSTAT (IBZ), THESE BENEFICIAL MICROORGANISMS WILL HAVE THE OPPORTUNITY TO REPOPULATE THE MICROBIOME IN A BENEFICIAL WAY THAT MAY PREVENT RECURRENCE IBZ AND FDX WERE SUPERIOR IN BIOFILM EXPERIMENTAL MODELS WITH IBZ SIGNIFICANTLY MORE EFFECTIVE AT KILLING C.DIFFICILE THAN VAN AND FDX TRIAL START-UP ACTIVITIES FOR A GROUND-BREAKING CLINICAL TRIAL IN PATIENTS WITH MULTIPLY-RECURRENT CDI (RCDI) HAVE BEEN INITIATED WITH THE FIRST PATIENT EXPECTED TO ENROLL IN THE NEXT QUARTER; A SUCCESSFUL TRIAL OUTCOME HAS THE POTENTIAL TO SHIFT THE PARADIGM OF TREATMENT AND PREVENTION OF RCDI FROM TWO AGENTS TO ONE WITH MUTUALLY CONSISTENT FEEDBACK FROM BOTH EMA AND FDA, ACURX IS WELL POSITIONED TO COMMENCE ITS INTERNATIONAL PHASE 3 REGISTRATION PROGRAM IN THE BROADER CDI PATIENT POPULATION ("ACUTE CDI") ACURX HAS PREVIOUSLY BEEN GRANTED FDA QIDP AND FAST-TRACK DESIGNATION AND HAS RECEIVED SME (SMALL AND MEDIUM-SIZED ENTERPRISE) DESIGNATION BY THE EMA STATEN ISLAND, N.Y.

ACURX PHARMACEUTICALS ANNOUNCES SCIENTIFIC POSTER PRESENTATION OF IBEZAPOLSTAT'S MICROBIOME PRESERVATION DATA IN MULTIPLY-RECURRENT C. DIFFICILE INFECTION

STATEN ISLAND, N.Y., JULY 8, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS SECOND QUARTER 2026 FINANCIAL RESULTS ON FRIDAY, AUGUST 14, 2026 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.

ACURX PHARMACEUTICALS TO DISCUSS SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 14, 2026 CONFERENCE CALL AND PROVIDE BUSINESS UPDATE

RESULTS ARE FROM ACURX'S ONGOING SCIENTIFIC COLLABORATION WITH LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) PARTIALLY UNDER A GRANT FROM HEALTH HOLLAND TO FURTHER STUDY THE MECHANISM OF ACTION OFDNA POL IIIC INHIBITORS LUMC HIGHLIGHTED ACURX'S NEW CLASS OF PROMISING ANTIMICROBIALS, IBEZAPOLSTAT AND RELATED ANALOGUES SPECIFICALLY TARGET GRAM-POSITIVE BACTERIA HIGH-RESOLUTION CRYO-ELECTRON MICROSCOPY RESOLVED THE STRUCTURE OF IBEZAPOLSTAT IN RELATIONSHIP TO THE BINDING POCKET OF A GRAM-POSITIVE DNA POL IIIC TO THE LEVEL OF 3.2 THE COMPANY'S PRECLINICAL PIPELINE INCLUDES DEVELOPMENT OF AN ORAL PRODUCT CANDIDATE FOR TREATMENT OF ABSSSI (ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS), WITH A DEVELOPMENT PROGRAM FOR POST-EXPOSURE PROPHYLAXIS OF INHALATION ANTHRAX BEING PLANNED IN PARALLEL IBEZAPOLSTAT HAS PREVIOUSLY BEEN GRANTED FDA QIDP AND FAST-TRACK DESIGNATIONS AND HAS RECEIVED SME (SMALL AND MEDIUM-SIZED ENTERPRISE) DESIGNATION BY THE EMA STATEN ISLAND,N.Y., JUNE 16, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY") IS A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF SMALL MOLECULE ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS.

ACURX PHARMACEUTICALS ANNOUNCES PRESENTATION OF RESULTS FROM LEIDEN UNIVERSITY MEDICAL CENTER PUBLIC-PRIVATE PARTNERSHIP FOR ITS DNA POL IIIC INHIBITORS AT THE LEIDEN EARLY DRUG DISCOVERY & DEVELOPMENT (LED3) SCIENTIFIC CONFERENCE

STATEN ISLAND, N.Y., MAY 12, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY CERTAIN FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

ACURX PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2026 RESULTS AND PROVIDES BUSINESS UPDATE

DNA POL IIIC INHIBITORS DEMONSTRATE THE UNEXPECTED BENEFIT OF GUT MICROBIOME PRESERVATION WHILE DEMONSTRATING SYSTEMIC ANTIBACTERIAL ACTIVITY NEUTROPENIC CD-1 MICE WERE INFECTED INTRAMUSCULARLY WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND SUBSEQUENTLY TREATED WITH ONE OF THREE ACURX DNA POL IIIC INHIBITORS, LINEZOLID, OR PLACEBO ADMINISTERED ORALLY ACURX COMPOUNDS ACHIEVED POTENTIALLY THERAPEUTIC PLASMA LEVELS AND REDUCED MRSA TISSUE BURDEN ACURX ANTIBIOTICS MAINTAINED A SUBSTANTIALLY HIGHER GUT MICROBIAL DIVERSITY AND A COMMUNITY STRUCTURE SIMILAR TO BASELINE AND DISTINCT FROM LINEZOLID UNLIKE LINEZOLID, ACX COMPOUNDS MAINTAIN BACTEROIDOTA-DOMINANT COMMUNITY STRUCTURE AND PREVENT PROTEOBACTERIA EXPANSION IN THE GASTROINTESTINAL TRACT DNA POL IIIC INHIBITORS DEMONSTRATE A CLASS EFFECT OF POTENTIALLY CLINICALLY-RELEVANT GUT MICROBIOME PRESERVATION WHILE DEMONSTRATING SYSTEMIC ANTIBACTERIAL ACTIVITY ACURX'S DNA POL IIIC INHIBITOR PRECLINICAL PRODUCT CANDIDATES ARE FDA QIDP AND FAST-TRACK ELIGIBLE AND TARGET GRAM-POSITIVE INFECTIONS CLASSIFIED AS SERIOUS THREAT PRIORITIES BY CDC STATEN ISLAND, N.Y., MAY 4, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED PRESENTATION OF A SCIENTIFIC POSTER AT THE 35TH CONGRESS OF ESCMID GLOBAL (EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES) HELD IN MUNICH, GERMANY FROM APRIL 17-21, 2026.

ACURX ANNOUNCES SCIENTIFIC POSTER PRESENTATION OF ITS DNA POL IIIC INHIBITORS' MICROBIOME EVALUATION AT ESCMID GLOBAL 2026

STATEN ISLAND, N.Y., APRIL 29, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS (NASDAQ: ACXP) (ACURX OR THE COMPANY), A FULLY-INTEGRATED BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS ANNOUNCED TODAY THAT DAVID P.

ACURX PHARMACEUTICALS TO PRESENT AT THE ALLIANCE GLOBAL PARTNERS (A.G.P) HEALTHCARE COMPANY SHOWCASE

STATEN ISLAND, NEW YORK--(NEWSFILE CORP. - APRIL 27, 2026) - ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("WE" OR "ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT WILL BE PARTICIPATING IN THE MARKET MOVERS INVESTOR SUMMIT ON TUESDAY MAY 5, 2026. THE PRESENTATION WILL TAKE PLACE AT 05:20 PM ET AT THE HISTORIC BANK OF NEW YORK.

ACURX PHARMACEUTICALS, INC. TO PRESENT AT THE MARKET MOVERS INVESTOR SUMMIT

STATEN ISLAND, N.Y., APRIL 20, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.

ACURX PHARMACEUTICALS TO DISCUSS FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 12, 2026 CONFERENCE CALL AND PROVIDE BUSINESS UPDATE

$2.5 MILLION UPFRONT WITH UP TO AN ADDITIONAL $4.6 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM WARRANTS STATEN ISLAND, N.Y., APRIL 16, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("WE" OR "ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING OF 825,085 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AT A PURCHASE PRICE OF $3.03 PER SHARE (OR PRE-FUNDED WARRANT IN LIEU THEREOF) PRICED AT-THE-MARKET UNDER NASDAQ RULES.

ACURX PHARMACEUTICALS, INC. ANNOUNCES CLOSING OF UP TO $7.1 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

$2.5 MILLION UPFRONT WITH UP TO AN ADDITIONAL $4.6 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM WARRANTS STATEN ISLAND, N.Y., APRIL 16, 2026 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("WE" OR "ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 825,085 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AT A PURCHASE PRICE OF $3.03 PER SHARE (OR PRE-FUNDED WARRANT IN LIEU THEREOF) IN A REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES.

Acurx Pharmaceuticals, Inc.

ACXP

Price

Financial Reports

No items found.

Press Releases

Acurx Pharmaceuticals, Inc.

ACXP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ACXP